Home > Efficacy: Clinical Trial Results

TAZVERIK® (tazemetostat) demonstrated efficacy in heavily pretreated follicular lymphoma patients, regardless of EZH2 mutation status

Overall response rate (ORR, primary endpoint):
Responses of 69% and 34% were achieved in patients with MT and WT EZH2, respectively1,2*

response rate
Complete Response
Partial Response

*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by independent review committee.

Back to top

Tumor response: in MT EZH2 patients2

response rate

98% (n=41/42) of patients
had a reduction in tumor size

Tumor response: in WT EZH2 patients2

respone rate

71% (n=34/48) of patients
had a reduction in tumor size

The tumor size was measured based on the maximum reduction in the sum of the products of the perpendicular diameters. Tumor response was unevaluable in 5 out of 53 WT EZH2 patients in the intent-to-treat population.

Back to top

Duration of response (DOR): TAZVERIK demonstrated sustained efficacy1,2

response rates

Of those who responded:

MT EZH2
59%(n=17/29) responded
for
≥6 months
21%(n=6/29) responded
for
≥12 months
WT EZH2
56%(n=10/18) responded
for
≥6 months
39%(n=7/18) responded
for
≥12 months

Median time to response for patients with MT EZH2 was 3.7 months (range: 1.6 to 10.9). Median time to response for patients with WT EZH2 was 3.9 months (range: 1.6 to 16.3).1

Back to top

Percentages are based on the Intent-to-Treat subjects within each group that achieved complete response or partial response.

MT=mutant-type; WT=wild-type; EZH2=enhancer of zeste homologue 2; ORR=overall response rate; CI=confidence interval; DOR=duration of response; NE=not estimable.

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Data on file.